Aura Biosciences, Inc. (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 11,822 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 11,822 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Aura Biosciences Price Performance

Shares of Aura Biosciences stock opened at $9.14 on Tuesday. The stock has a market capitalization of $456.54 million, a P/E ratio of -5.28 and a beta of 0.33. Aura Biosciences, Inc. has a one year low of $6.63 and a one year high of $12.38. The business’s 50 day simple moving average is $9.82 and its two-hundred day simple moving average is $8.54.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. Sell-side analysts expect that Aura Biosciences, Inc. will post -1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. JMP Securities upped their target price on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Cowen restated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, Scotiabank boosted their price objective on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $23.00.

Hedge Funds Weigh In On Aura Biosciences

Several large investors have recently made changes to their positions in AURA. American Century Companies Inc. purchased a new position in Aura Biosciences in the second quarter worth about $119,000. American International Group Inc. boosted its holdings in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after buying an additional 3,782 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Aura Biosciences during the 1st quarter worth $144,000. SG Americas Securities LLC bought a new stake in Aura Biosciences during the third quarter valued at about $169,000. Finally, Barclays PLC grew its stake in shares of Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after acquiring an additional 43,897 shares during the period. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.